Clinical trial
gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent…
NCT00133497 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00133497 |
|---|---|
| Title | gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of the Cytomegalovirus gB/MF59 Vaccine in Preventing Systemic Cytomegalovirus Infection in Healthy Adolescent Females |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Biological, Drug |
| Interventions | MF-59, Placebo, CMV gB vaccine |
| Enrollment | 409 |
| Start date | Jun 1, 2006 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Aug 23, 2005 |
| Last update posted | Jul 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: